Physician profile
Cassandra Black
NPI 1699267070
$799.86
in general payments reported to CMS, 2019-2025
10 companies · $551 in 2025
The $551 reported for 2025 was more than what 75% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $18.74 · 2024: $230 · 2025: $551.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $800.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $799.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $182.62 | 2024-2025 | Biktarvy, Veklury |
| Insmed, INC. | $153.70 | 2024-2025 | Arikayce |
| Melinta Therapeutics, LLC | $106.35 | 2024-2025 | Rezzayo, Orbactiv, Vabomere |
| Paratek Pharmaceuticals, INC. | $81.69 | 2024-2025 | Nuzyra |
| Ferring Pharmaceuticals INC. | $79.24 | 2024-2025 | Rebyota |
| Abbvie INC. | $76.41 | 2023-2025 | Dalvance |
| Merck Sharp & Dohme LLC | $62.80 | 2024-2025 | Zerbaxa, Dificid, Recarbrio |
| Shionogi INC | $25.49 | 2024 | Fetroja |
| Aimmune Therapeutics, INC. | $15.83 | 2025 | Zenpep |
| Viiv Healthcare Company | $15.73 | 2025 | Dovato |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cassandra Black listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.